Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Ian Hu, MD
CONTACT
Lead
M.D. Anderson Cancer Center
With
Primary Objectives: 1. Assess tolerability/safety of this combination and determine the maximum tolerated dose (MTD) of CTX-009. 2. Assess 6 month progression-free survival to the combination therapy according to RECIST 1.1 Secondary Objectives: 1. Assess objective response rate (ORR) 2. Assess duration of response (DOR) 3. Assess overall survival (OS) 4. Assess progression free survival (PFS)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
